A Lethal Outcome After Overdose of Rivastigmine Transdermal Patch in an Elderly Patient
PDF
Cite
Share
Request
Case Report
P: 42-45
March 2021

A Lethal Outcome After Overdose of Rivastigmine Transdermal Patch in an Elderly Patient

J Turk Soc Intens Care 2021;19(1):42-45
1. Yozgat Bozok Üniversitesi Tıp Fakültesi, Anesteziyoloji ve Reanimasyon Anabilim Dalı, Yozgat, Türkiye
2. Malatya Eğitim ve Araştırma Hastanesi, Yoğun Bakım Kliniği, Malatya, Türkiye
3. Malatya Eğitim ve Araştırma Hastanesi, Anesteziyoloji ve Reanimasyon Kliniği, Malatya, Türkiye
No information available.
No information available
Received Date: 20.04.2020
Accepted Date: 28.08.2020
Publish Date: 15.03.2021
PDF
Cite
Share
Request

ABSTRACT

Rivastigmine is a cholinesterase inhibitor with oral or transdermal forms used in the treatment of dementia. In this study, the case of a 92-year-old male with Alzheimer’s type dementia was presented with rivastigmine toxicity. The patient who was considered to have acute cholinergic syndrome after accidental multiple administration of eight rivastigmine patches by the relative of the patient, was admitted to the intensive care unit. After treatment with pralidoxime, there was still no improvement in the clinical findings. The patient became unconsciousness and developed respiratory depression and was provided with endotracheal intubation and mechanical ventilator support. The patient who developed multiple organ failure died on the 20th day of hospitalisation. It should be noted that incorrect transdermal drug applications can lead to fatal results. Patients and their relatives should be trained on the correct application of these drugs and appropriate patient counselling should be provided during the treatment process.

Keywords: Rivastigmine, transdermal, toxicity, pralidoxime

References

1
Lanctôt KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, et al. Neuropsychiatric signs and symptoms of Alzheimer’s disease: New treatment paradigms. Alzheimers Dement (NY) 2017;3:440-9.
2
Desai AK, Grossberg GT. Rivastigmine for Alzheimer’s disease. Expert Rev Neurother 2005;5:563-80.
3
Sadowsky CH, Farlow MR, Meng X, Olin JT. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. Int J Clin Pract 2010;64:188-93.
4
Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine. Ther Adv Drug Saf 2018;9:171-8.
5
Lampert A, Seiberth J, Haefeli WE, Seidling HM. A systematic review of medication administration errors with transdermal patches. Expert Opin Drug Saf 2014;13:1101-14.
6
Ma M, Dorstyn D, Ward L, Prentice S. Alzheimers’ disease and caregiving: a meta-analytic review comparing the mental health of primary carers to controls. Aging Ment Health 2018;22:1395-405.
7
Gulhan R. Rational Drug Use in Elderly. Med J Okmeydani Train Res Hosp 2013;29:99-105.
8
Malaiya MK, Jain A, Pooja H, Jain A, Jain D. Controlled delivery of rivastigmine using transdermal patch for effective management of alzheimer’s disease. J Drug Deliv Sci Technol 2018;45:408-14.
9
Winblad B, Kawata AK, Beusterien KM, Thomas SK, Wimo A, Lane R, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Geriatr Psychiatry 2007;22:485-91.
10
Hoffman RS, Manini AF, Russell-Haders AL, Felberbaum M, Mercurio-Zappala M. Use of pralidoxime without atropine in rivastigmine (carbamate) toxicity. Hum Exp Toxicol 2009;28:599-602.
11
Lövborg H, Jönsson AK, Hägg S. A fatal outcome after unintentional overdosing of rivastigmine patches. Curr Drug Saf 2012;7:30-2.
12
Lee DH, Choi YH, Cho KH, Yun SY, Lee HM. A case of rivastigmine toxicity caused by transdermal patch. Am J Emerg Med 2011;29:695.
13
Lefèvre G, Sedek G, Huang HL, Saltzman M, Rosenberg M, Kiese B, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007;47:471-8.
14
Yoshiki S, Yoshito K, Tomohiro Y, Yuji F, Kiyotaka U, et al. Acute cholinergic syndrome in a patient with mild Alzheimer’s type dementia who had applied a large number of rivastigmine transdermal patches on her body. Clinical Toxicology 2017;55:1008-10.
15
Sener S, Ozsarac M. Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression. Emerg Med J 2006;23:82-5.
16
Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2015;9:CD001191.
17
Pawar KS, Bhoite RR, Pillay CP, Chavan SC, Malshikare DS, Garad SG. Continuous pralidoxime infusion versus repeated bolus injection to treat organophosphorus pesticide poisoning: a randomised controlled trial. Lancet 2006;368:2136-41.
18
Syed S, Gurcoo SA, Farooqui AK, Nisa W, Sofi K, Wani TM. Is the World Health Organization-recommended dose of pralidoxime effective in the treatment of organophosphorus poisoning? A randomized, double-blinded and placebo-controlled trial. Saudi J Anaesth 2015;9:49-54.
19
Saz EU, Yurtseven A, Kilinç MA, Sari F, Ağin H. The First Use of Pralidoxime in a Child With Rivastigmine Poisoning. Pediatr Emerg Care 2018;34:184-6.
20
Johnson S, Peter JV, Thomas K, Jeyaseelan L, Cherian AM. Evaluation of two treatment regimens of pralidoxime (1 gm single bolus dose vs 12 gm infusion) in the management of organophosphorus poisoning. J Assoc Physicians India 1996;44:529-31.
21
Eddleston M, Eyer P, Worek F, Juszczak E, Alder N, Mohamed F, et al. Pralidoxime in acute organophosphorus insecticide poisoning - A randomised controlled trial. PLoS Med 2009;6:1-12.
22
Peter JV, Moran JL, Graham P. Oxime therapy and outcomes in human organophosphate poisoning: an evaluation using meta-analytic techniques. Crit Care Med 2006;34:502-10.
23
Worek F, Thiermann H, Wille T. Oximes in organophosphate poisoning: 60 years of hope and despair. Chem Biol Interact 2016;259:93-8.
2024 ©️ Galenos Publishing House